JP2016527251A5 - - Google Patents

Download PDF

Info

Publication number: JP2016527251A5
Authority: JP; Japan
Prior art keywords: less; dosage form; unit dosage; administered; fasted state
Prior art date: 2014-07-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2016529842A

Other languages

English (en)

Japanese (ja)

Other versions

JP6453876B2 (ja

JP2016527251A (ja

Filing date

2014-07-22

Publication date

2017-08-31

2014-07-22 Application filed filed Critical

2014-07-22 Priority claimed from PCT/US2014/047701 external-priority patent/WO2015013336A1/en

2016-09-08 Publication of JP2016527251A publication Critical patent/JP2016527251A/ja

2017-08-31 Publication of JP2016527251A5 publication Critical patent/JP2016527251A5/ja

2019-01-16 Application granted granted Critical

2019-01-16 Publication of JP6453876B2 publication Critical patent/JP6453876B2/ja

Status Expired - Fee Related legal-status Critical Current

2034-07-22 Anticipated expiration legal-status Critical

Links

IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical group CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 claims description 19
229960000509 metaxalone Drugs 0.000 claims description 15
238000004090 dissolution Methods 0.000 claims description 8
239000002552 dosage form Substances 0.000 claims 61
239000002245 particle Substances 0.000 claims 1
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
229940105580 skelaxin Drugs 0.000 description 3
239000011230 binding agent Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 1
229960003305 alfaxalone Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
238000009490 roller compaction Methods 0.000 description 1
238000013112 stability test Methods 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1

JP2016529842A 2013-07-22 2014-07-22 メタキサロンの製剤 Expired - Fee Related JP6453876B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361857199P	2013-07-22	2013-07-22
US61/857,199		2013-07-22
PCT/US2014/047701 WO2015013336A1 (en)	2013-07-22	2014-07-22	Formulation of metaxalone

Publications (3)

Publication Number	Publication Date
JP2016527251A JP2016527251A (ja)	2016-09-08
JP2016527251A5 true JP2016527251A5 (2)	2017-08-31
JP6453876B2 JP6453876B2 (ja)	2019-01-16

Family

ID=52393794

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016529842A Expired - Fee Related JP6453876B2 (ja)	2013-07-22	2014-07-22	メタキサロンの製剤

Country Status (17)

Country	Link
US (7)	US20160159756A1 (2)
EP (1)	EP3024440B1 (2)
JP (1)	JP6453876B2 (2)
KR (1)	KR20160039608A (2)
CN (1)	CN105431136B (2)
AU (1)	AU2014293193A1 (2)
BR (1)	BR112016001395A8 (2)
CA (1)	CA2918908A1 (2)
CL (1)	CL2016000171A1 (2)
DK (1)	DK3024440T3 (2)
IL (1)	IL243447A0 (2)
MX (1)	MX365591B (2)
MY (1)	MY181226A (2)
RU (1)	RU2684914C2 (2)
SG (2)	SG10201800491RA (2)
WO (1)	WO2015013336A1 (2)
ZA (1)	ZA201600408B (2)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
US20200405693A1 (en)	2019-06-25	2020-12-31	Primus Pharmaceuticals, Inc.	Reduced dose metaxalone formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5500331A (en)	1994-05-25	1996-03-19	Eastman Kodak Company	Comminution with small particle milling media
US5478705A (en)	1994-05-25	1995-12-26	Eastman Kodak Company	Milling a compound useful in imaging elements using polymeric milling media
US7714006B1 (en) *	2001-12-03	2010-05-11	King Pharmaceuticals Research & Development, Inc.	Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) *	2001-12-03	2002-06-18	Elan Pharmaceuticals, Inc.	Method for increasing the bioavailability of metaxalone
AU2003276688A1 (en) *	2002-09-02	2004-03-19	Sun Pharmaceutical Industries Limited	Pharmaceutical composition of metaxalone with enhanced oral bioavailability
ATE415946T1 (de) *	2003-08-08	2008-12-15	Elan Pharma Int Ltd	Neue metaxalon-zusammensetzungen
US20050276844A1 (en) *	2004-03-08	2005-12-15	Spiridon Spireas	Bioavailable compositions of metaxalone and processes for producing the same
US20120093928A1 (en) *	2007-08-09	2012-04-19	Ranbaxy Laboratories Limited	Oral metaxalone compositions
AP3138A (en) *	2009-04-24	2015-02-28	Iceutica Pty Ltd	Production of encapsulated nanoparticles at high volume fractions
MX360019B (es)	2009-04-24	2018-10-15	Iceutica Pty Ltd	Una formulación novedosa de metaxalona.
RU2499595C1 (ru) *	2012-07-03	2013-11-27	Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации	Способ повышения качества жизни и улучшения способностей к выполнению профессиональной деятельности у пациентов с остеоартрозом, выполняющих водительские и диспетчерско-операторские функции

2014
- 2014-07-22 SG SG10201800491RA patent/SG10201800491RA/en unknown
- 2014-07-22 JP JP2016529842A patent/JP6453876B2/ja not_active Expired - Fee Related
- 2014-07-22 CA CA2918908A patent/CA2918908A1/en not_active Abandoned
- 2014-07-22 MX MX2016001019A patent/MX365591B/es active IP Right Grant
- 2014-07-22 EP EP14830224.3A patent/EP3024440B1/en not_active Not-in-force
- 2014-07-22 CN CN201480041432.5A patent/CN105431136B/zh not_active Expired - Fee Related
- 2014-07-22 MY MYPI2016700223A patent/MY181226A/en unknown
- 2014-07-22 AU AU2014293193A patent/AU2014293193A1/en not_active Abandoned
- 2014-07-22 BR BR112016001395A patent/BR112016001395A8/pt not_active IP Right Cessation
- 2014-07-22 US US14/906,703 patent/US20160159756A1/en not_active Abandoned
- 2014-07-22 RU RU2016105763A patent/RU2684914C2/ru active
- 2014-07-22 WO PCT/US2014/047701 patent/WO2015013336A1/en not_active Ceased
- 2014-07-22 KR KR1020167001873A patent/KR20160039608A/ko not_active Ceased
- 2014-07-22 SG SG11201600264TA patent/SG11201600264TA/en unknown
- 2014-07-22 DK DK14830224.3T patent/DK3024440T3/en active
2016
- 2016-01-03 IL IL243447A patent/IL243447A0/en unknown
- 2016-01-19 ZA ZA2016/00408A patent/ZA201600408B/en unknown
- 2016-01-22 CL CL2016000171A patent/CL2016000171A1/es unknown
2017
- 2017-09-05 US US15/696,125 patent/US20180148422A1/en not_active Abandoned
2018
- 2018-11-13 US US16/190,104 patent/US20190152930A1/en not_active Abandoned
2020
- 2020-05-15 US US16/875,931 patent/US20210101873A1/en not_active Abandoned
2022
- 2022-02-07 US US17/666,465 patent/US20220235017A1/en not_active Abandoned
2023
- 2023-07-12 US US18/221,353 patent/US20240150304A1/en not_active Abandoned
2024
- 2024-11-21 US US18/955,748 patent/US20250084043A1/en not_active Abandoned

Publication	Publication Date	Title
Rishabha et al.	2010	Preparation and evaluation of disintegrating properties of Cucurbita maxima pulp powder
US20170000799A1 (en)	2017-01-05	Oral pharmaceutical composition
JP2016512248A5 (2)	2017-03-30
WO2015132708A1 (en)	2015-09-11	Pharmaceutical composition of roflumilast
CN104940127A (zh)	2015-09-30	含有埃索美拉唑的药物组合物
JP2014501267A (ja)	2014-01-20	メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法
JP2010540547A5 (2)	2012-11-01
EA031255B1 (ru)	2018-12-28	Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
JP2010095545A (ja)	2010-04-30	ケイアルデヒド含有量の保持方法
BR122023026625A2 (pt)	2024-01-16	Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo
Shanmugam et al.	2011	Formulation and evaluation of sustained release matrix tablets of Losartan potassium
WO2015115453A1 (ja)	2015-08-06	口腔内速崩壊性固形製剤用組成物
JP2016527251A5 (2)	2017-08-31
JP6204141B2 (ja)	2017-09-27	口腔内速崩壊性固形製剤用組成物
JP2015120758A5 (2)	2015-08-13
JP2016512247A5 (2)	2017-03-30
CN106943367B (zh)	2020-07-14	一种马来酸阿法替尼片及其制备方法
CN104758941A (zh)	2015-07-08	一种利用羟丙基纤维素为粘合剂实现快速溶出的口服片剂
CN104666262A (zh)	2015-06-03	一种利伐沙班片
CN103933004B (zh)	2016-05-25	一种来曲唑片剂及其制备方法
Shavi et al.	2009	Multiparticulate drug delivery system of aceclofenac: development and in vitro studies
Jain et al.	2014	Formulation and characterization of liquisolid tablets of valsartan for improvement of dissolution rate
CN102781440A (zh)	2012-11-14	治疗帕金森氏症的医药组合物及其制备方法
CN103961333B (zh)	2020-02-21	甲磺酸帕罗西汀胶囊及其制备方法
CN106913543B (zh)	2021-06-04	一种达比加群酯片剂及其制备方法